amikacin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, kanamycin and bekanamycin derivatives (obtained from Streptomyces kanamyceticus) 157 37517-28-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amikacin
  • amicacin
  • amikacillin
  • arikace
  • lukadin
  • amikacin sulfate
  • amikacin hydrate
A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.
  • Molecular weight: 585.61
  • Formula: C22H43N5O13
  • CLOGP: -4.12
  • LIPINSKI: 3
  • HAC: 18
  • HDO: 13
  • TPSA: 331.94
  • ALOGS: -1.07
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 98 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 25.61 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.88 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 22, 1981 FDA APOTHECON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 263.98 19.32 111 10486 17257 46658208
Pathogen resistance 156.80 19.32 57 10540 6003 46669462
Drug reaction with eosinophilia and systemic symptoms 132.79 19.32 83 10514 29465 46646000
Septic shock 128.85 19.32 106 10491 57787 46617678
Multiple organ dysfunction syndrome 128.50 19.32 101 10496 51609 46623856
Deafness 114.64 19.32 61 10536 16007 46659458
Ototoxicity 100.50 19.32 27 10570 1042 46674423
Dysphonia 84.70 19.32 70 10527 38344 46637121
Thrombocytopenia 83.56 19.32 122 10475 126459 46549006
Klebsiella infection 79.69 19.32 36 10561 6626 46668839
Geotrichum infection 79.51 19.32 19 10578 453 46675012
Systemic candida 75.59 19.32 27 10570 2700 46672765
Toxic skin eruption 74.45 19.32 42 10555 12345 46663120
Mycobacterium abscessus infection 74.18 19.32 19 10578 607 46674858
Pseudomonas infection 72.29 19.32 38 10559 9720 46665745
Eosinophilia 66.81 19.32 46 10551 19171 46656294
Sepsis 64.81 19.32 113 10484 135901 46539564
Rash maculo-papular 61.86 19.32 51 10546 27823 46647642
Tinnitus 60.09 19.32 50 10547 27623 46647842
Aphonia 59.02 19.32 31 10566 7914 46667551
Febrile neutropenia 54.98 19.32 86 10511 94541 46580924
Nephropathy toxic 52.30 19.32 28 10569 7426 46668039
Myelosuppression 51.44 19.32 28 10569 7675 46667790
Acute kidney injury 51.41 19.32 143 10454 235712 46439753
Toxic epidermal necrolysis 49.93 19.32 41 10556 22237 46653228
Hepatotoxicity 49.81 19.32 43 10554 24966 46650499
Paradoxical drug reaction 49.23 19.32 19 10578 2357 46673108
Haemoptysis 48.10 19.32 43 10554 26146 46649319
Hepatocellular injury 47.47 19.32 45 10552 29477 46645988
Mycobacterium avium complex infection 47.23 19.32 19 10578 2629 46672836
Pain 46.95 19.32 25 10572 476923 46198542
Encephalopathy 46.18 19.32 47 10550 33542 46641923
Enterococcal infection 45.55 19.32 25 10572 6962 46668503
Pyrexia 44.22 19.32 176 10421 348626 46326839
Bronchopulmonary aspergillosis 43.91 19.32 25 10572 7471 46667994
Fatigue 43.10 19.32 45 10552 608652 46066813
Candida infection 41.80 19.32 37 10560 22203 46653262
Osteomyelitis bacterial 39.40 19.32 9 10588 175 46675290
Acinetobacter infection 39.11 19.32 14 10583 1408 46674057
Immune reconstitution inflammatory syndrome 38.75 19.32 21 10576 5704 46669761
Bacteraemia 38.00 19.32 29 10568 14150 46661315
Off label use 36.92 19.32 177 10420 379664 46295801
Product use in unapproved indication 36.60 19.32 70 10527 90203 46585262
Acute respiratory distress syndrome 36.36 19.32 34 10563 21888 46653577
Fall 35.79 19.32 15 10582 329082 46346383
Clostridium difficile colitis 35.13 19.32 31 10566 18522 46656943
Multiple-drug resistance 34.33 19.32 15 10582 2550 46672915
Mycobacterial infection 33.62 19.32 13 10584 1620 46673845
Nosocomial infection 33.61 19.32 13 10584 1622 46673843
Arthralgia 33.14 19.32 21 10576 364582 46310883
Sputum increased 32.71 19.32 13 10584 1743 46673722
Mucormycosis 32.62 19.32 14 10583 2278 46673187
Cholestasis 32.27 19.32 35 10562 26858 46648607
Acute generalised exanthematous pustulosis 31.47 19.32 22 10575 9383 46666082
Hepatitis 30.34 19.32 37 10560 32178 46643287
Herpes simplex hepatitis 30.15 19.32 8 10589 294 46675171
Hypertransaminasaemia 29.93 19.32 15 10582 3473 46671992
Retinal ischaemia 29.74 19.32 8 10589 310 46675155
Haemorrhage intracranial 29.73 19.32 24 10573 12700 46662765
Neutropenic colitis 29.70 19.32 13 10584 2219 46673246
Antithrombin III 29.01 19.32 7 10590 174 46675291
Leukopenia 27.70 19.32 53 10544 68290 46607175
Hepatosplenic candidiasis 27.56 19.32 7 10590 216 46675249
Pancreatitis acute 27.47 19.32 31 10566 24841 46650624
Neutropenia 27.43 19.32 83 10514 143121 46532344
Cough 27.35 19.32 114 10483 230135 46445330
Headache 26.90 19.32 42 10555 478310 46197155
Klebsiella bacteraemia 26.51 19.32 10 10587 1166 46674299
Granulomatous liver disease 26.03 19.32 9 10588 817 46674648
Coagulopathy 25.63 19.32 26 10571 18473 46656992
Granulomatosis with polyangiitis 25.63 19.32 11 10586 1791 46673674
Dysbiosis 25.52 19.32 8 10589 534 46674931
Vulvovaginitis 25.36 19.32 7 10590 299 46675166
Polyneuropathy 25.18 19.32 21 10576 11623 46663842
Rhinocerebral mucormycosis 24.72 19.32 6 10591 153 46675312
Kussmaul respiration 24.72 19.32 6 10591 153 46675312
Pancytopenia 24.08 19.32 57 10540 85001 46590464
Chemotherapeutic drug level increased 23.82 19.32 6 10591 179 46675286
Deafness neurosensory 23.70 19.32 14 10583 4480 46670985
Hyperlactacidaemia 23.45 19.32 11 10586 2204 46673261
Corneal opacity 23.38 19.32 8 10589 704 46674761
Febrile bone marrow aplasia 22.84 19.32 16 10581 6846 46668619
Mycobacterium chelonae infection 22.68 19.32 7 10590 444 46675021
Overgrowth fungal 22.64 19.32 5 10592 83 46675382
Nasopharyngitis 22.33 19.32 4 10593 153994 46521471
Neonatal respiratory distress syndrome 22.05 19.32 11 10586 2522 46672943
Pain in extremity 22.00 19.32 16 10581 258664 46416801
Guillain-Barre syndrome 21.97 19.32 12 10585 3310 46672155
Agranulocytosis 21.74 19.32 26 10571 22159 46653306
Retinal artery occlusion 21.40 19.32 9 10588 1393 46674072
Product administered to patient of inappropriate age 21.40 19.32 11 10586 2685 46672780
Acute hepatic failure 20.96 19.32 21 10576 14700 46660765
Endocarditis candida 20.78 19.32 4 10593 32 46675433
Malaise 20.64 19.32 27 10570 331205 46344260
Infective pulmonary exacerbation of cystic fibrosis 20.34 19.32 18 10579 10789 46664676
Bone marrow failure 20.10 19.32 29 10568 29640 46645825
Electrocardiogram QT prolonged 19.81 19.32 39 10558 51286 46624179
Lower respiratory tract infection bacterial 19.78 19.32 6 10591 359 46675106
Tinea versicolour 19.47 19.32 4 10593 46 46675419

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ototoxicity 215.87 17.97 60 13070 1336 29938012
Drug resistance 210.37 17.97 123 13007 20010 29919338
Septic shock 173.30 17.97 174 12956 63433 29875915
Pathogen resistance 105.63 17.97 58 13072 8352 29930996
Product use in unapproved indication 105.51 17.97 145 12985 73548 29865800
Mycobacterium abscessus infection 103.55 17.97 28 13102 560 29938788
Deafness 92.02 17.97 57 13073 10268 29929080
Drug reaction with eosinophilia and systemic symptoms 88.79 17.97 84 13046 28404 29910944
Multiple organ dysfunction syndrome 82.06 17.97 119 13011 63368 29875980
Thrombocytopenia 67.37 17.97 170 12960 136874 29802474
Fatigue 63.17 17.97 31 13099 320642 29618706
Mycobacterium chelonae infection 62.44 17.97 19 13111 586 29938762
Acute kidney injury 61.74 17.97 260 12870 273582 29665766
Rash maculo-papular 60.89 17.97 65 13065 25353 29913995
Electrocardiogram QT prolonged 59.66 17.97 76 13054 35759 29903589
Fall 58.41 17.97 6 13124 181866 29757482
Drug ineffective 57.50 17.97 297 12833 340090 29599258
Toxic skin eruption 53.73 17.97 42 13088 10973 29928375
Enterococcal infection 50.49 17.97 36 13094 8188 29931160
Brain abscess 49.59 17.97 24 13106 2657 29936691
Tuberculosis 48.77 17.97 35 13095 8042 29931306
Febrile bone marrow aplasia 44.16 17.97 33 13097 8064 29931284
Death 43.41 17.97 56 13074 357227 29582121
Deafness neurosensory 43.00 17.97 21 13109 2372 29936976
Candida infection 41.66 17.97 42 13088 15320 29924028
Blood pressure measurement 39.80 17.97 10 13120 148 29939200
Acute respiratory distress syndrome 39.40 17.97 50 13080 23422 29915926
Multiple-drug resistance 38.90 17.97 21 13109 2920 29936428
Hepatotoxicity 37.56 17.97 43 13087 18102 29921246
Nocardiosis 35.75 17.97 21 13109 3434 29935914
Aspergillus infection 35.44 17.97 32 13098 10182 29929166
Deafness bilateral 33.87 17.97 14 13116 1068 29938280
Hypertransaminasaemia 33.47 17.97 21 13109 3864 29935484
Pain 33.43 17.97 17 13113 172624 29766724
Pseudomonas infection 32.80 17.97 31 13099 10451 29928897
Immune reconstitution inflammatory syndrome 32.54 17.97 29 13101 9072 29930276
Pyrexia 32.32 17.97 230 12900 294259 29645089
Treatment failure 32.29 17.97 56 13074 34623 29904725
Myocardial infarction 31.72 17.97 8 13122 125617 29813731
Myelosuppression 31.62 17.97 26 13104 7296 29932052
Acute generalised exanthematous pustulosis 31.37 17.97 24 13106 6074 29933274
Vascular pseudoaneurysm thrombosis 31.14 17.97 7 13123 62 29939286
Cholestasis 31.06 17.97 46 13084 24904 29914444
Leukopenia 31.06 17.97 73 13057 56086 29883262
Acoustic neuroma 31.03 17.97 8 13122 132 29939216
Nephropathy toxic 30.53 17.97 30 13100 10609 29928739
Hepatocellular injury 30.34 17.97 46 13084 25425 29913923
Off label use 29.87 17.97 199 12931 249091 29690257
Eosinophilia 29.25 17.97 42 13088 22118 29917230
Hypoacusis 28.41 17.97 33 13097 14106 29925242
Hypofibrinogenaemia 28.25 17.97 14 13116 1631 29937717
Inflammatory marker increased 26.88 17.97 17 13113 3171 29936177
Mycobacterium avium complex infection 26.80 17.97 16 13114 2695 29936653
Klebsiella infection 26.74 17.97 23 13107 6864 29932484
Pancytopenia 26.70 17.97 90 13040 84962 29854386
Lymphocyte count decreased 26.45 17.97 37 13093 19018 29920330
Drug ineffective for unapproved indication 26.35 17.97 28 13102 10852 29928496
Linear IgA disease 25.65 17.97 13 13117 1589 29937759
Incision site pain 25.65 17.97 14 13116 1990 29937358
Red blood cells urine positive 25.53 17.97 13 13117 1604 29937744
Stenotrophomonas infection 25.48 17.97 13 13117 1611 29937737
Cardiac valve vegetation 25.30 17.97 9 13121 456 29938892
Bronchopulmonary aspergillosis 25.23 17.97 29 13101 12255 29927093
Hyperbilirubinaemia 25.18 17.97 34 13096 16908 29922440
Protein urine present 25.01 17.97 19 13111 4756 29934592
Sepsis 24.71 17.97 128 13002 146267 29793081
Systemic candida 23.96 17.97 15 13115 2749 29936599
Posterior reversible encephalopathy syndrome 23.96 17.97 24 13106 8683 29930665
Candida sepsis 23.90 17.97 11 13119 1088 29938260
Mycobacterium fortuitum infection 23.58 17.97 7 13123 198 29939150
Toxic neuropathy 23.12 17.97 8 13122 373 29938975
Weight bearing difficulty 23.00 17.97 10 13120 865 29938483
Respiratory distress 22.92 17.97 47 13083 32925 29906423
Allodynia 22.59 17.97 9 13121 624 29938724
Agranulocytosis 22.50 17.97 37 13093 21905 29917443
Disseminated intravascular coagulation 22.21 17.97 37 13093 22134 29917214
Sepsis neonatal 21.89 17.97 7 13123 255 29939093
Sputum purulent 21.75 17.97 8 13122 446 29938902
Scedosporium infection 21.53 17.97 9 13121 706 29938642
Hepatitis fulminant 21.35 17.97 16 13114 3925 29935423
Dehydration 21.28 17.97 14 13116 123525 29815823
Aeromonas infection 21.26 17.97 7 13123 280 29939068
Fusarium infection 21.12 17.97 10 13120 1054 29938294
Headache 20.62 17.97 30 13100 182276 29757072
Vestibular disorder 20.42 17.97 9 13121 804 29938544
Malaise 20.37 17.97 26 13104 166936 29772412
Cardiac failure congestive 20.12 17.97 6 13124 84401 29854947
Meningitis tuberculous 20.05 17.97 8 13122 557 29938791
Dizziness 19.30 17.97 35 13095 194874 29744474
Product dose omission issue 19.30 17.97 8 13122 91623 29847725
Mucormycosis 19.25 17.97 17 13113 5251 29934097
Febrile neutropenia 19.18 17.97 95 13035 106598 29832750
Gallstone ileus 19.16 17.97 4 13126 24 29939324
Hepatosplenic candidiasis 18.96 17.97 6 13124 211 29939137
Shock 18.82 17.97 35 13095 22824 29916524
Flavobacterium infection 18.78 17.97 5 13125 94 29939254
Syncope 18.56 17.97 7 13123 84896 29854452
Acinetobacter infection 18.55 17.97 9 13121 1001 29938347
Pericarditis tuberculous 18.44 17.97 5 13125 101 29939247
C-reactive protein increased 18.30 17.97 51 13079 43422 29895926
Neuropathy peripheral 18.21 17.97 70 13060 70405 29868943
Fungal sepsis 18.17 17.97 8 13122 713 29938635
Skin hyperpigmentation 18.13 17.97 13 13117 2981 29936367
Pulmonary cavitation 18.12 17.97 8 13122 718 29938630
Renal tubular disorder 17.99 17.97 16 13114 4990 29934358

Pharmacologic Action:

SourceCodeDescription
ATC D06AX12 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
ANTIBIOTICS FOR TOPICAL USE
Other antibiotics for topical use
ATC J01GB06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
AMINOGLYCOSIDE ANTIBACTERIALS
Other aminoglycosides
ATC J01RA06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC S01AA21 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0000946 Aminoglycosides
FDA EPC N0000175477 Aminoglycoside Antibacterial
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:61015 nephrotoxins
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Infection due to Pseudomonas aeruginosa indication 11218009
Staphylococcal meningitis indication 12166008
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Pneumonia due to Pseudomonas indication 41381004
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Osteomyelitis indication 60168000
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Septicemia due to Serratia indication 82091000
Cholangitis indication 82403002 DOID:9446
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Escherichia coli meningitis indication 192655005
Proteus pneumonia indication 195888009
Sepsis of the newborn indication 206376005
Neonatal pneumonia indication 233619008
Diverticulitis of gastrointestinal tract indication 271366000
Neonatal meningitis indication 276674008
Proteus septicemia indication 300986008
Escherichia coli urinary tract infection indication 301011002
Proteus meningitis indication 302877009
Bacterial urinary infection indication 312124009
Infectious disorder of joint indication 363162000
Meningitis due to Klebsiella mobilis indication 420585007
Nosocomial pneumonia indication 425464007
Bacterial meningitis due to Gram-negative bacteria indication 425887005
Pneumonia due to Gram negative bacteria indication 430395005
Sepsis due to Pseudomonas indication 448813005
Sepsis due to Gram negative bacteria indication 449082003
Urinary tract infection caused by Klebsiella indication 369001000119100
Skin and Skin Structure Serratia Infection indication
Pseudomonas Aeruginosa Biliary Tract Infection indication
Klebsiella Septicemia indication
Complicated Urinary Tract Infections indication
Complicated UTI with Pseudomonas Aeruginosa indication
Pseudomonas Aeruginosa Meningitis indication
Pseudomonas Aeruginosa Osteomyelitis indication
Skin and Skin Structure Proteus Infection indication
Serratia Meningitis indication
Skin and Skin Structure Staphylococcus Infection indication
Enterobacter Meningitis indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Burn Wound Infections indication
Gram-Negative Aerobic Bacillary Pneumonia indication
Complicated Bacterial Peritonitis indication
Complicated Proteus UTI indication
Complicated Urinary Tract Infection due to Acinetobacter indication
Pseudomonas Aeruginosa Joint Infection indication
Serratia Osteomyelitis indication
Serratia Complicated UTI indication
Enterobacter Pneumonia indication
Necrotizing enterocolitis in fetus OR newborn off-label use 2707005
Pyrexia of unknown origin off-label use 7520000
Enteric campylobacteriosis off-label use 18081009
Acute tuberculosis off-label use 25629007
Pseudotuberculosis off-label use 36753006
Infection by Yersinia enterocolitica off-label use 80960004
Pulmonary tuberculosis off-label use 154283005 DOID:2957
Synergy for Neonatal Meningitis off-label use
Citrobacter Complicated UTI off-label use
Synergy for Group B Streptococcal Septicemia off-label use
Citrobacter Septicemia off-label use
Citrobacter Meningitis off-label use
Synergy for Bacterial Meningitis off-label use
Citrobacter Osteomyelitis off-label use
Synergy for P. Aeruginosa Infection in Cystic Fibrosis off-label use
Listeria Monocytogenes Septicemia off-label use
Skin and Skin Structure Citrobacter Infection off-label use
Skin and Skin Structure Acinetobacter Infection off-label use
Synergy for Staphylococcal Infections off-label use
Citrobacter Pneumonia off-label use
Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa off-label use
Synergy for Staphylococcal Endocarditis off-label use
Hypocalcemia contraindication 5291005
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Tinnitus contraindication 60862001
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Pregnancy, function contraindication 289908002
Vertigo contraindication 399153001
Disorder of the 8th Cranial Nerve contraindication
Amikacin Toxicity contraindication
Infant Botulism contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.04 acidic
pKa2 12.95 acidic
pKa3 13.39 acidic
pKa4 13.72 acidic
pKa5 9.4 Basic
pKa6 7.84 Basic
pKa7 7.41 Basic
pKa8 6.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 590MG BASE/8.4ML ARIKAYCE KIT INSMED INC N207356 Sept. 28, 2018 RX SUSPENSION, LIPOSOMAL INHALATION Sept. 28, 2025 TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNULLTIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
EQ 590MG BASE/8.4ML ARIKAYCE KIT INSMED INC N207356 Sept. 28, 2018 RX SUSPENSION, LIPOSOMAL INHALATION Sept. 28, 2030 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) Enzyme Km 4.20 WOMBAT-PK

External reference:

IDSource
84319SGC3C UNII
4019602 VUID
N0000147698 NUI
D00865 KEGG_DRUG
39831-55-5 SECONDARY_CAS_RN
C0002499 UMLSCUI
CHEBI:2637 CHEBI
AKN PDB_CHEM_ID
CHEMBL177 ChEMBL_ID
CHEMBL1164318 ChEMBL_ID
CHEMBL4208954 ChEMBL_ID
DB00479 DRUGBANK_ID
D000583 MESH_DESCRIPTOR_UI
37768 PUBCHEM_CID
3492 INN_ID
10894 IUPHAR_LIGAND_ID
641 RXNORM
2863 MMSL
35287 MMSL
4165 MMSL
d00087 MMSL
002781 NDDF
004899 NDDF
1269009 SNOMEDCT_US
387266001 SNOMEDCT_US
48836000 SNOMEDCT_US
4018137 VANDF
4019602 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6166 INJECTION 250 mg INTRAMUSCULAR ANDA 22 sections
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6167 INJECTION 250 mg INTRAMUSCULAR ANDA 22 sections
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0703-9032 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 20 sections
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0703-9040 INJECTION, SOLUTION 1 g INTRAMUSCULAR ANDA 20 sections
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 23155-290 INJECTION, SOLUTION 250 mg INTRAMUSCULAR ANDA 20 sections
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 23155-785 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 20 sections
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 23155-786 INJECTION, SOLUTION 1 g INTRAMUSCULAR ANDA 20 sections
amikacin sulfate HUMAN PRESCRIPTION DRUG LABEL 1 25021-173 INJECTION, SOLUTION 250 mg INTRAVENOUS ANDA 23 sections
Amikacin Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 63323-815 INJECTION, SOLUTION 250 mg INTRAVENOUS ANDA 19 sections
Amikacin Sulfate Injection, 500 mg/2ml HUMAN PRESCRIPTION DRUG LABEL 1 70297-996 INJECTION 500 mg INTRAMUSCULAR Export only
Amikacin Sulfate Injection, 500 mg/2ml HUMAN PRESCRIPTION DRUG LABEL 1 71309-996 INJECTION 500 mg INTRAMUSCULAR Export only
ARIKAYCE HUMAN PRESCRIPTION DRUG LABEL 1 71558-590 SUSPENSION 590 mg RESPIRATORY (INHALATION) NDA 33 sections